Nexien BioPharma, Inc. (NXEN)

Nexien BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Total Valuation

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 5, 2026	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Market Capitalization	0	1	2	4	5	3
Market Cap Growth	-99.17%	-47.97%	-39.49%	-24.47%	90.11%	-45.30%
Enterprise Value	0	1	3	4	5	3
Last Close Price	0.00	0.02	0.04	0.06	0.09	0.05

Price Ratios

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 5, 2026	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
PB Ratio	-0.02	-3.30	-9.08	-32.16	-363.58	-413.89

Financial Efficiency

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 5, 2026	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Debt / Equity Ratio	-0.83	-0.86	-1.08	-1.88	-2.39	-1.88
Net Debt / Equity Ratio	-0.81	-0.85	-0.94	-0.89	-1.08	-0.19
Quick Ratio	0.02	0.01	0.12	0.48	0.46	0.37
Current Ratio	0.02	0.01	0.15	0.51	0.65	0.78
Return on Equity (ROE)	-	-	-	-	-	-2058.62%
Return on Assets (ROA)	-655.83%	-411.28%	-210.72%	-469.81%	-4769.09%	-988.36%
Return on Capital Employed (ROCE)	26.30%	43.10%	112.10%	479.60%	13384.90%	41423.20%

Yields

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 5, 2026	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Earnings Yield	-2657.65%	-20.08%	-15.81%	-16.56%	-37.14%	-101.41%
Buyback Yield / Dilution	-8.06%	-6.19%	-7.73%	-4.44%	-2.76%	-5.64%

Data Source: S&P Global Market Intelligence Last updated: May 14, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 6, 2026

Data Sources Report a data error